Abstract
Functional exploration of neuroendocrine tumor (NET) has the benefit of getting several radiopharmaceuticals. The main ones are MIBG, radiolabeled somatostatin analogues, 18F-DOPA, and 18FFDG. Their main indications are reminded in medullary thyroid cancer, pheochromocytoma, and paraganglioma and digestive endocrine tumors.
Résumé
L’exploration fonctionnelle des TNE a l’avantage de disposer de plusieurs radiopharmaceutiques. Les principaux sont la MIBG, les analogues radiomarqués de la somatostatine, la 18FDOPA et le 18F-FDG. Leurs principales indications sont rappelées dans le cancer médullaire de la thyroïde, les phéochromocytomes et paragangliomes et les tumeurs endocrines digestives.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Références
Abgral R, Leboulleux S, Déandreis D, et al (2011) Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 96(3): 665–671
Balogova S, Talbot JN, Nataf V, et al (2013) 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging 40(6): 943–966
Garin E, Le Jeune F, Devillers A, et al (2009) Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 50(6): 858–864
Geijer H, Breimer LH (2013) Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 40(11): 1770–1780
Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, et al (2013) Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL. EVA Investigators. J Clin Endocrinol Metab 98(1): E162–E173
Giraudet AL, Vanel D, Leboulleux S, et al (2007) Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92(11): 4185–4190
Ilias I, Pacak K (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89(2): 479–491
Kloos RT, Eng C, Evans DB, et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19(6): 565–612
Lamberts SW, Bakker WH, Reubi JC, Krenning EP (1990) Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323(18): 1246–1249
Oudoux A, Salaun PY, Bournaud C, et al (2007) Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 92(12): 4590–4597
Slavikova K, Montravers F, Treglia G, et al (2013) What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma? Curr Radiopharm 6(2): 96–105
Solanski KK, Bomanji J, Moyes J, et al (1992) A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13(7): 513–521. Review
Taïeb D, Timmers HJ, Hindié E, et al (2012) EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39(12): 1977–1995
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tenenbaum, F. La médecine nucléaire en 2013 et les tumeurs neuroendocrines (TNE) : un choix de plus en plus personnalisé de radiopharmaceutiques. Oncologie 15, 524–528 (2013). https://doi.org/10.1007/s10269-013-2347-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-013-2347-x